Skip to main content

Table 2 Results of different screening studies for celiac disease, CD

From: Serological screening for celiac disease in schoolchildren in Jordan. Is height and weight affected when seropositive?

Country Age (years) Number Antibody* Prevalence Reference
United Kingdom 7.5 5470 1. tTG
2. IgA EmA
1:101 (1.0%)† (Bingley et al 2004)
The Netherlands 2 to 4 6127 1. IgA EmA 1:82 (1.2%)‡ (Csizmadia et al 1999)
The USA 2 to 18 1281 1. IgA EmA 1:320 (0.3%)§ (Fasano et al 2003)
Finland 7 to 16 3654 1. IgA EmA and IgA tTG 1:73 (1.4%)|| (Maki et al 2003)
Turkey Adult blood donors 2 000 1. IgA tTG 1:87 (1.1%)‡ (Tatar et al 2004)
North America and Western Europe Children Large population Biopsy 0.5% to 1.6%. AHRQ No. 104 Celiac Disease 2004
  1. tTG: tissue transglutaminase; EmA; anti-endomysium antibody.
  2. *: 1. = the test(s) performed as screening test(s). 2. = the test performed for confirmation of the screening test.
  3. † The prevalence is based on subjects confirmed positive with a second serological marker.
  4. ‡ The prevalence is based on subjects positive on only one serological marker.
  5. §The prevalence is based on one serological marker (IgA EmA), but all tested positive on IgA tTG as well.
  6. || Two tests were carried out at the same time, and the serological prevalence is based on subjects positive on both tests.